Ipamorelin: The Selective GH Secretagogue

Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone releasing peptide (GHRP) class. It acts as a ghrelin mimetic at the GHS-R1a (growth hormone secretagogue receptor), triggering GH release from pituitary somatotrophs through a mechanism entirely distinct from GHRH. Among the GHRPs — which include GHRP-2, GHRP-6, hexarelin, and others — ipamorelin stands out for its selectivity: it produces robust GH secretion with minimal stimulation of cortisol, prolactin, or appetite. This selectivity profile makes ipamorelin the most commonly recommended GHRP for routine use.

The GHRP Mechanism

The ghrelin receptor system (GHS-R1a) is the molecular target for all GHRPs. Ghrelin, a 28-amino acid peptide primarily produced in the stomach, activates this receptor to stimulate GH release and appetite. The GHRPs are synthetic ghrelin mimetics that bind GHS-R1a with varying receptor activation profiles.

Crucially, GHS-R1a stimulation promotes GH release through a pathway that is entirely distinct from GHRH receptor signaling. GHRH activates adenylyl cyclase (cAMP pathway) in somatotrophs; ghrelin/GHRPs activate phospholipase C (IP3/DAG pathway). At the pituitary, these two pathways are strongly synergistic — each enhances the responsiveness of somatotrophs to the other, explaining the multiplicative GH responses observed when a GHRH analog and a GHRP are combined.

Selectivity: Why Ipamorelin Differs

The selectivity issue is where ipamorelin distinguishes itself from older GHRPs. GHRP-6 and GHRP-2, the original research GHRPs, produce substantial increases in cortisol and prolactin in addition to GH. GHRP-6 is notorious for stimulating appetite — a useful property in some contexts but generally unwanted for anti-aging or body composition applications. Hexarelin produces the largest GH pulses of the class but desensitizes rapidly and elevates cortisol significantly.

Ipamorelin produces GH pulses comparable to GHRP-2 with minimal cortisol or prolactin elevation in clinical studies. The appetite stimulation seen with GHRP-6 is largely absent. This favorable selectivity profile means users get the benefits of GH stimulation without the confounding effects of elevated cortisol (catabolic, immunosuppressive) or prolactin (reproductive effects, water retention).

The selectivity appears to reflect differential receptor interaction at secondary sites beyond the primary GHS-R1a binding site. Ipamorelin is a more selective ligand that activates GH release pathways without fully activating the downstream signaling that triggers ACTH/cortisol and prolactin release.

Human and Animal Pharmacology

Ipamorelin has been studied in clinical trials for several indications, including post-operative ileus (where it received Phase II investigation for GI motility effects) and adult GH deficiency. The GI data is interesting — GHS-R1a receptors are expressed throughout the gastrointestinal tract, and ghrelin mimetics including ipamorelin have prokinetic effects that may be relevant for conditions involving impaired GI motility.

Pharmacokinetic studies show a half-life of approximately 2 hours following subcutaneous injection, with peak GH elevation at 60-90 minutes. The pulse is clean and discrete — GH rises substantially, then returns to baseline over 3-4 hours. This pulse profile, unlike the sustained elevation of exogenous GH, preserves the pulsatility that maintains GH receptor sensitivity.

Dosing and Administration

The standard ipamorelin dose is 200-300mcg administered subcutaneously, with frequency ranging from once daily (before sleep) to three times daily. The most evidence-supported protocol stacks ipamorelin with a GHRH analog (CJC-1295 without DAC or modified GRF 1-29) for synergistic GH release.

Timing recommendations center on the pre-sleep dose as the most impactful — naturally, the largest GH pulse of the day occurs in early slow-wave sleep, and co-administering ipamorelin and a GHRH analog approximately 30-60 minutes before sleep amplifies this natural pulse rather than creating an out-of-phase stimulation.

The standard stack protocol: ipamorelin 200-300mcg + modified GRF 1-29 100mcg subcutaneously, taken 30-60 minutes before sleep. Some protocols add a morning dose for additional GH pulsatility.

Expected Physiological Effects

The GH stimulation from ipamorelin-containing protocols produces the downstream effects of enhanced GH/IGF-1 signaling over weeks to months: improved body composition (lean mass gain, fat loss at comparable caloric intake), enhanced recovery from exercise and injury, improved sleep quality, and the general tissue repair effects associated with adequate GH signaling.

The effects are more gradual than exogenous recombinant GH administration and fall within the physiological range, which is generally preferable from a safety standpoint. IGF-1 levels typically rise modestly — to the upper-normal physiological range — rather than to the supraphysiological levels seen with pharmaceutical GH.

FAQ

Q: How does ipamorelin compare to MK-677 for GH stimulation?

MK-677 (ibutamoren) is an oral ghrelin mimetic acting on the same GHS-R1a receptor as ipamorelin. MK-677 produces sustained GH elevation (24-hour effect from once-daily dosing) rather than discrete pulses. Ipamorelin produces pulsatile GH release more analogous to physiological patterns. MK-677 also stimulates appetite substantially; ipamorelin does not.

Q: Does ipamorelin suppress natural GH production?

Unlike exogenous GH, peptide secretagogues work by stimulating the pituitary to produce and release more endogenous GH. There is no evidence of HPGA suppression with GHRP or GHRH analog use. The pituitary retains its normal function, which is a meaningful safety advantage over exogenous GH.

Q: What is a typical cycle length for ipamorelin?

Most protocols run 3-6 month cycles. Some practitioners use continuous low-dose protocols without cycling for general anti-aging applications. The absence of pituitary suppression reduces the urgency for cycling compared to exogenous hormone use.

Track your supplements in Optimize.